Drugs / Matrix-M Adjuvant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02370589 | Feb 2015 → Apr 2016 | Ebola hemorrhagic fever | Novavax | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT06485752 Comparator | Nov 2024 → Feb 2025 | COVID-19 | Novavax | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-07-24 | Novavax | Results Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study novavax.com ↗
Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration |
| 2023-10-02 | Novavax | Regulatory R21/Matrix-M™ Malaria Vaccine with Novavax’s Adjuvant Technology Receives WHO Recommendation novavax.com ↗
Today, the World Health Organization (WHO) announced its recommendation of the R21/Matrix-M™ malaria vaccine to prevent malaria in children following advice from its Strategic Advisory Group of Experts (SAGE) and Malaria Policy Advisory Group (MPAG). |
| 2022-10-12 | Novavax | Results Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants novavax.com ↗
These data further demonstrate the consistent immunogenicity and safety profile of the Novavax COVID-19 vaccine as a booster, regardless of previous vaccine history, |
| 2021-12-02 | Novavax | Results Novavax Statement on Omicron Variant Response novavax.com ↗
Matrix-M adjuvant was shown to increase and broaden immune response , with a demonstrated ability to stimulate high levels of neutralizing antibodies and T-cell responses. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-07-24 | Novavax | Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study novavax.com ↗ |
| 2023-10-02 | Novavax | R21/Matrix-M™ Malaria Vaccine with Novavax’s Adjuvant Technology Receives WHO Recommendation novavax.com ↗ |
| 2022-10-12 | Novavax | Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants novavax.com ↗ |
| 2021-12-02 | Novavax | Novavax Statement on Omicron Variant Response novavax.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Matrix-M Adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02370589 ↗ |
| Route | Intramuscular | “Day 0: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM” NCT02370589 ↗ |